Graphical Abstract Highlights d Ultra-deep rRNA-depleted RNA sequencing of 144 localized prostate tumors d Fusion gene profiles differentiate localized from metastatic disease d Widespread RNA circularization events define clinically distinct tumor subtypes d Functional screening reveals pervasive circular isoformspecific essentiality SUMMARY
INTRODUCTION
Prostate cancer is the most frequently diagnosed non-cutaneous cancer in men worldwide (Mohler et al., 2016) . Localized tumors can often be cured by definitive local therapy (Cooperberg and Carroll, 2015) , but once a tumor migrates outside of the gland, incurable metastatic disease may be inevitable (Jackson et al., 2018; Xie et al., 2017) . Understanding the biology of localized, curable prostate tumors is thus a clinical imperative.
As a direct result, the genome of localized prostate tumors has been well studied (Berger et al., 2011; Cancer Genome Atlas Research Network, 2015; Espiritu et al., 2018; Fraser et al., 2017; Wedge et al., 2018) , and the transcriptome has been extensively evaluated using microarrays and low-coverage polyadenylation (poly-A)-enriched RNA sequencing (RNA-seq) (Cancer Genome Atlas Research Network, 2015; Ramaswamy et al., 2003; Singh et al., 2002; Zhao et al., 2017b) . These analyses have hinted at a diverse transcriptome harboring prognostic information (Berger et al., 2011; Prensner et al., 2011 Prensner et al., , 2014 Zhao et al., 2017a) .
A poorly characterized component of the prostate cancer transcriptome is circular transcripts (circRNAs), which have been implicated in other diseases (Guarnerio et al., 2016; Memczak et al., 2013; Weng et al., 2017) . circRNAs form a covalently closed loop that increases stability and creates biomarker potential (Memczak et al., 2015) while eluding poly-A capture (Chen, 2016) . As a result, full diversity of the prostate cancer transcriptome and its implication remained hidden.
To fill this gap, we performed ultra-deep non-poly-A RNA-seq on 144 localized prostate tumors, linked to long-term clinical follow-up. This allowed us to map the transcriptome in unprecedented depth, identifying 1,233 unique fusion genes (21 recurrent and 2 prognostic) and 76,311 distinct circRNAs. The global burden of circRNAs was correlated with tumor aggressivity, and 171 circRNAs essential to prostate cancer cell proliferation were identified. These data show that the cancer transcriptome harbors numerous functional entities not observable with traditional molecular strategies.
RESULTS

Transcriptome Profiling of Localized Prostate Cancer
To assess the transcriptome of prostate cancer, we assembled a cohort of 144 patients with sporadic, localized, intermediate-risk disease (CPC-GENE, Canadian Prostate Cancer Genome Network). All patients were treated by radical prostatectomy, with median 6.5-years follow-up (Table S1 ). A treatment-naive surgical specimen was subjected to pathology review and then macro-dissected to a minimum of 70% tumor cellularity. The RNA of each sample was quantified via strand-specific, ribo-somal RNA-depleted RNA-seq, with a median of 382 million (M) ± 138 M reads per tumor.
After processing through standard quality-control and dataprocessing pipelines (Table S1; Figure S1A ), the median tumor harbored 118,753 ± 7,373 transcripts, derived from 17,958 ± 333 coding and 17,742 ± 1,579 non-coding genes. There were 18,340 transcripts present in all tumors, including 15,112 protein-coding isoforms such as AR, MYC, and KLK3 (Figures 1A and 1B) . High-abundance transcripts were often ubiquitous: 12,797 of the 13,416 most abundant were detected in every sample. By contrast, an intriguing subset of 180 high-abundance transcripts were detected in five or fewer samples (i.e., 3.5% of patients), making them candidate enhancer-hijacking events (Weischenfeldt et al., 2017) .
The Cancer Genome Atlas (TCGA) network identified integrated prostate cancer subtypes (Cancer Genome Atlas Research Network, 2015) . To link these to transcriptomic subtypes, we applied unsupervised machine learning to the top quartile of transcripts detected in all samples, ranked by interquartile range. These 4,585 transcripts included 3,905 proteincoding and 680 non-coding (353 antisense, 286 lncRNA [long non-coding RNA], 12 snRNA [small nuclear RNA] and 29 snoRNA [small nucleolar RNA]) and delineated five patient subtypes (P1-P5) and five RNA subtypes (R1-R5; Figures 1C, S1B, and S1C). The average silhouette score was 0.76 for sample clustering and 0.39 for gene clustering ( Figure S1D ). Samples in P1-P3 had higher global genomic instability, assessed as the percent of the genome with a copy-number aberration (PGA, Student's t test, p = 3.29 3 10 À4 ; Figure S1E ). P1 also had a higher proportion of prostate cancer driver genes deleted than other subtypes, including the tumor suppressors NKX3-1 (78% versus 42%; p = 1.6 3 10 À3 , proportions test), TP53 (50% versus 19%; p = 8.0 3 10 À3 , proportions test), and PTEN (60% versus 30%; p = 8.7 3 10 À4 , proportions test; Figure S1F ). Intriguingly, 63% of samples in P1 harbored intraductal carcinoma and cribriform architecture (IDC/CA) relative to 20%-40% of patients in other subtypes (p = 0.013; c 2 test). While IDC/CA is associated with aggressive prostate cancer (Bö ttcher et al., 2018; Chua et al., 2017) , the rate of biochemical relapse (BCR) did not differ among the patient subtypes (log-rank test, p = 0.88; Figure S1G ).
Samples in P2 had the highest proportion of CHD1 deletions (46% versus 13%; p = 3.4 3 10 À4 ; proportions test; Figure S1F ), reminiscent of a TCGA subtype characterized by aberrant SPOP and CHD1 (Cancer Genome Atlas Research Network, 2015).
Systematic comparison of our transcriptomic subtypes to the TCGA ones confirmed the similarity of P2 to the TCGA subtype distinguished by SPOP and CHD1 mutations. By contrast, the other transcriptomic subtypes did not closely match specific TCGA subtypes ( Figure S1H ).
We also compared our transcriptomic subtypes to previously defined copy-number alteration (CNA) ones : 44% (15/34) of samples in P3 correspond to a genomic subtype characterized by recurrent sub-telomeric amplifications, while P4 and P5 correspond to a copy-number quiet genomic subtype (72%; 49/68; Figures S1I and S1J). Despite these specific membership overlaps, overall similarity between CNA and transcriptomic subtypes was low (Adjusted Rand index = 0.134), suggesting that multiple transcriptomic phenotypes can emerge from single genomic ones.
To assess the functional hallmarks of each RNA subtype, we used g:Profiler (Reimand et al., 2016) to identify significantly enriched pathways (false discovery rate [FDR] < 0.05; Table S1; Figure S1K ). Since R5 was enriched in immune-related pathways, we associated the abundance of these genes with immune activity. The mean abundance of genes in R5 was positively correlated with the percentage of infiltrating immune cells (Yoshihara et al., 2013 ) (Spearman's r = 0.66; p < 2.2 3 10 À16 ) and cytolytic activity (Spearman's r = 0.67, p = 7.20 3 10 À19 ; Figure S1L ). These pathway differences suggest that transcriptomic subtypes may be initiated or driven differently.
Fusion Genes Are Associated with Aggressive Localized Disease
To identify candidate tumor-specific isoforms, we next evaluated the landscape of fusion genes. Our deep-sequencing coverage revealed fusions not detectable in previous RNA-seq studies, with 1,223 unique fusions identified (Table S1 ). The median tumor harbored 14 ± 13 distinct fusions (median ± SD). There were 21 recurrent fusions (R10% of the cohort; Figure 1D ). Of the recurrent fusions, 13 were read-through fusions, including the SLC45A3:ELK4 fusion seen in almost all patients (142/146), as expected (Rickman et al., 2009) . A previously unreported read-through fusion involved the SCHLAP1 lncRNA and UBE2E3 mRNA. SCHLAP1 is associated with aggressive prostate cancer (Bhandari et al., 2019; Prensner et al., 2013) , but this fusion was not associated with disease relapse. We also identified a read-through fusion between RP11-356O9.1 and TTC6, genes flanking FOXA1 but on opposite strand. Both this fusion and TBCEL:TECTA were associated with BCR ( Figures  S1M and S1N) , and tumors harboring both were at elevated risk for relapse (p = 0.006; hazard ratio [HR] = 5.00, 95% confidence interval [CI] = 1.6-15.7; Figure S1O ).
We next examined the relationship between each pairwise combination of the 21 recurrent fusions. Recurrent fusions cooccurred more than expected by chance (permutation test with 10 6 iterations; p = 1.0 3 10 À6 ; Figure 1D ). Interestingly, the tumor-initiating TMPRSS2:ERG (T2E) fusion was neither significantly co-occurring nor mutually exclusive with others (hypergeometric test; Q > 0.05). Rather, SCHLAP1:UBE2E3 fusion co-occurred with TBCEL:TECTA, SAMD5:SASH1, and AC004066.3:PPA2 fusions (hypergeometric test; Q < 0.05). Concordant with the concept of nimbosus, SCHLAP1:UBE2E3 fusion was also strongly associated with IDC/CA ( Figure 1D ; proportions test; FDR = 0.0015) (Chua et al., 2017) .
To understand interplay between somatic mutations and the transcriptome, we explored associations between the recurrent fusions with 40 previously published genomic driver events (Cancer Genome Atlas Research Network, 2015; Fraser et al., 2017) . Recapitulating previous results, T2E fusion was associated with TP53 and PTEN mutations, while T2E-negative tumors were enriched for SPOP and CHD1 mutations ( Figure S1P ). SPOP mutations co-occurred with PRCAT47:CDYL2 fusion (proportions test; Q = 0.045). These associations corroborate previous findings that SPOP mutations drive prostate tumorigenesis through a mechanism independent of T2E fusion and PTEN loss (Blattner et al., 2017) .
To determine whether the fusion landscape changes with transition to lethal castrate-resistant disease, we analyzed fusions in metastatic lesions from the Stand Up 2 Cancer (SU2C) cohort using the same pipeline ( Figure 1E ) (Robinson et al., 2015) . Fusions were twice as common in metastatic as in localized tumors, despite lower sequencing coverage for metastases (median 28 versus 14; p = 1.2 3 10 À8 ; Mann-Whitney U test). There were 33 recurrent fusions, including TBCEL:TECTA found in 34% of metastases. Unlike in localized disease, fusions in metastatic lesions did not tend toward either mutual exclusivity or cooccurring (permutation test, 10 6 iterations). Overall, 17 fusions (C) Sample (K = 5) and RNA (K = 5) subtypes discovered by consensus clustering of 144 samples using the top 25% of RNAs (n = 4,582) ordered by interquartile range. Clinical covariates per patient are shown in the covariate bar to the right. (D) In the primary area, each row represents a fusion gene that was identified in more than 10% of samples, while each column indicates a patient. Bottom: Clinical characteristic of patients. Colors in the primary area indicate lines of evidence supporting the fusion, and a triangle indicates whether an event is a read-through fusion. Samples are sorted by the number of recurrent fusion genes as indicated by the barplot above. Right: Dotmap indicates whether fusions are significantly co-occurring or mutually exclusive. The bottom heatmap shows the association between fusion events and clinical covariates. (E) Recurrent fusions identified in more than 10% of the SU2C metastatic transcriptomes. Similar to (D) , primary area shows patients with the fusion, while the adjacent barplot indicates proportion of cohort with the fusion. The barplot on the right shows the significance of enrichments and depletion tests performed between the two cohorts. See also Figure S1 and Table S1. were significantly enriched and 6 significantly depleted in metastatic relative to localized tumors, including 12 recurrent in metastatic lesions but undetected in localized ones (logistic regression and Fisher's exact test; Q < 0.05; Figure 1E ). This shift in fusion genes may be indicative of selective adaptation to treatment and adaptation to metastatic sites or disease progression, and it highlights new candidate metastasis drivers.
The circRNA Landscape of Localized Prostate Cancer
The ubiquity of read-through fusions in prostate cancer suggests dysfunctional transcription and splicing machinery, which could affect splicing events like RNA circularization (Chen, 2016) . Our data provide a unique opportunity to assess circRNAs. Using CIRCexplorer , we identified 76,311 distinct circRNAs (R2 back-splicing reads [BSRs]) in the CPC-GENE cohort (Figure 2A ). BSRs generally followed a negative binomial distribution (Figures S2A and S2B) , allowing calculation of circRNA abundance via FPKM (fragments per kilobase of transcript per million mapped reads) quantification. Using linear fusion transcript information, we detected 62 fusion-circRNAs (f-circRNAs), which occurred more frequently in tumors with greater extent ( Figure S2C ). Because of the lack of recurrence for f-circRNAs, we elected to focus on canonical circRNAs, but these f-circRNAs represent a class of intriguing biomarker candidates.
To validate the identified circRNAs, we exploited the fact that circRNAs are resistant to exonuclease degradation and thus can be enriched by RNase R treatment. We performed RiboMinus RNA-seq with and without RNase R treatment in four prostate cancer cell lines: LNCaP, V16A, 22Rv1, and PC-3. This analysis identified 34,286 circRNAs, of which 33,806 were enriched by at least 1.5-fold after RNase R treatment (Figure 2A ). We focused on the high-confidence set of 25,036 circRNAs that were both RNase R-enriched in cell lines and detected (with at least two BSRs) in tumors ( Figure 2A ).
To further verify the high-confidence circRNAs, we analyzed an independent cohort of 49 prostate tumors (NGS-ProToCol, Table S1 ). About 87% of our high-confidence circRNAs were detected in this validation cohort ( Figure S2D ), and their abundance was highly correlated (Spearman's r = 0.71, p < 2.2 3 10 À16 ; Figure S2E ). These circRNAs map to genomic regions that replicate earlier than expected by chance (p = 1 3 10 À6 ), suggesting a link between circRNAs and replication timing.
To identify prostate-specific circRNAs, we compared our circRNAs to known annotations in circBase (Gla zar et al., 2014) . Intriguingly, 67% of all circRNAs were detected in only 1 for the random forest predictor on held-out dataset, 95% CI: 0.85-0.88 (mean from 10,000 iterations). (G) Correlation between circRNA and its linear counterpart against circRNA mean abundance. Kendall's tau and its p value give correlation between the mean abundance of individual circRNAs and their correlation with parental gene. (H) Distribution of the maximum log 2 transformed ratio between circRNA and its linear counterpart across samples. circRNAs with or without significant higher abundance compared to their linear counterparts were grouped as dominant and others, respectively. Inset shows log 2 mean FPKM for circRNAs in the two categories; Mann-Whitney U test p = 2.8 3 10 À17 , CLES = 0.72. See also Figure S2 and Table S2 . of the 11 cell or tissue sources evaluated ( Figures 2B, 2C , S2F, and S2G). To determine the extent of patient specificity in circRNA-abundance profiles, we calculated the fraction of molecules detected in each sample for three categories: parental linear, all linear, and circular. Here, the circular and linear forms refer to gene-level circular and linear RNA transcripts, respectively (STAR Methods). Indeed, this value was much lower for circular forms, suggesting a higher patient-specific profile (Figures 2D, S2H, and S2J) . The high values for parental linear forms indicated that circRNAs tended to be produced from genes present in almost all tumors. Indeed, parental genes were enriched for housekeeping processes related to centrosome, spindle, and ATPase activity ( Figure S2K ).
The enrichment of parental genes in specific pathways encouraged us to quantify features for genes that circularize. The parental genes of circRNAs were longer and had more splicing events ( Figures S2L-S2N (Salzman et al., 2013) , and were enriched for previously reported regulators of circRNAs biogenesis (Figures S2Q-S2S) (Conn et al., 2015; Kramer et al., 2015; Li et al., 2017; Liang et al., 2017; Shi et al., 2017; ENCODE Project Consortium, 2012; Zhang et al., 2014) . We evaluated eight features for each gene (STAR Methods; Table S2 ; Figure S2T ) and quantified their ability to distinguish genes that produced circRNAs from those that do Patients were ranked according to increasing CRI and divided into quartile groups (Q1-Q4). (B and C) Comparison of BCR-free rate between the stable (Q2, Q3) and extreme (Q1, Q4) CRI groups in CPC-GENE (B) and NGS-ProToCol (C) cohorts. HR and 95% CIs (numbers in parentheses) for extremes group is shown. For NGS-ProToCol dataset, samples with BCR annotation (n = 40) were used. (D) Distribution of metastatic disease as a function of CRI in the pooled cohort (hypergeometric test). (E) Relationship between transcript abundance and BCR in the CPC-GENE dataset. y and x axes show HR of circRNAs and their linear counterparts, respectively. See also Figure S3 and Table S3 . not ( Figure 2E ). A random forest model generated from eight features on 50% of the dataset was able to accurately predict the presence of RNA circularization events in the held-out set (area under the curve [AUC] = 0.86 ± 0.004, 95% CI: 0.85 ± 0.005-0.87 ± 0.002, mean and SD calculated from 10,000 iterations; Figures  2F and S2U ). Predicted parental genes were longer and detected in more samples (Mann-Whitney U test, p < 2.2 3 10 À16 , Figures S2V and S2W ). These results suggested that some information required for circRNA production is embedded in the genome.
While high-abundance circRNAs tend to have high-abundance linear counterparts (Figures 2G and S2X) , the correlation between circular and linear transcripts was generally low (Figure 2G, y axis) . Indeed, only 3.0% of circRNAs were statistically correlated in abundance to their linear counterparts (FDR < 0.05), indicating dynamic regulation of circRNA production. While an overall positive correlation between the degrees of alternativeand back-splicing was observed ( Figure S2Y ), the correlation varied among genes ( Figure S2Z ). In $97% of cases, the linear form had higher abundance than the circRNAs (Salzman et al., 2012) . However, 127 circRNAs show significantly higher abundance than their linear counterparts (FDR < 0.05; Figure 2H ).
circRNA Abundance Defines Clinically Distinct Tumor Subtypes
To assess whether circRNAs defined specific subtypes, we performed consensus clustering on all 144 tumors. In contrast to linear RNAs, we did not observe distinct subtypes. Rather, the strongest pattern of circRNAs corresponded to their overall abundance in each sample ( Figure S3A ). To quantify this, we calculated a circRNA index (CRI, STAR Methods) and grouped patients into quartiles ( Figure 3A ; Q1-Q4). Higher CRI was significantly associated with more read-through and ETS fusion events (Mann-Whitney U test; p = 1.4 3 10 À2 and 2.3 3 10 À3 ; CLES = 0.62 and 0.65; Figure S3B ; Table S3 ), supporting the involvement of common machinery in fusion and circRNA production .
Tumors with either very high (Q4) or very low (Q1) CRI had elevated rates of BCR after therapy ( Figure S3C ). Indeed, patients with extreme circRNA distributions (Q1, Q4) had significantly worse prognosis than those with stable distributions (Q2, Q3; Figures 3B and S3D ). This association was replicated in the independent NGS-ProToCol cohort ( Figure 3C ). The extreme CRI groups were also associated with higher incidence of metastasis in pooled cohort ( Figure 3D ). A similar analysis of circRNA parental genes revealed no such association ( Figures S3E-S3G ). To further characterize the clinical relevance of circRNAs, we evaluated the association between individual circRNAs and BCR (STAR Methods) and performed the same analysis for their linear counterparts. The range and variation of HRs for circRNAs (log 2 HR: À2.97-6.03) was larger than for the linear forms (À1.99-2.02). Importantly, the low correlation ( Figure 3E , r = 0.07, p = 1.50 3 10 À19 ) of HRs between circular and linear forms indicated different underlying biological mechanisms. Thus, both global circRNA abundance and the abundances of specific circRNAs were associated with clinical outcome, suggesting that these circRNAs are not simply transcriptional noise but may have specific oncogenic functions.
Functional Screening Identifies Essential circRNAs
To evaluate the functional importance of specific circRNAs, we selected the 2,000 most abundant ones in prostate cancer cell lines for small hairpin RNA (shRNA)-based loss-of-function screen (Moffat et al., 2006) . To specifically silence circRNAs, we designed shRNAs that target back-splicing sites ( Figure 4A ) (Yu et al., 2017) . We also designed shRNAs targeting linear transcript outside of circRNA exon(s) to assess function of the linear form ( Figure 4A ). The resulting library targeted 1,507 circRNAs and 1,075 of their linear counterparts with at least two shRNAs each ( Figure 4B ; Table S4 ). After library transduction and puromycin selection in the four prostate cancer cell lines, a sampling population at day 0 (T0) and two evolving populations at days 8 (T8) and 16 (T16) were collected and sequenced ( Figure S4A ; STAR Methods).
To determine the efficacy of our screen, we applied MaGeCK to identify depleted linear transcripts (Li et al., 2014b) . For all screens, positive controls showed a significantly higher dropout (Mann-Whitney U test; p = 1.7 3 10 À28 , CLES = 0.86), while negative controls did not (Mann-Whitney U test; p = 0.92; size and color of dot shows log 2 (FC) of treatment over control. The two KD replicates were merged so that mean FC and the bigger p value are represented. (H) Cumulative distribution for gene -log 10 (p value) in LNCaP CRISPR screen data from the Achilles project (Aguirre et al., 2016) . Dashed line shows p = 0.05. See also Figure S4 and Table S4 .
Figures 4C and S4B-S4D
). The dropout level, as measured by fold change of normalized shRNA abundance, was highly correlated between time points . Further, the depleted linear transcripts in our screens demonstrated significantly higher dropout in the Achilles shRNA and CRISPR (Mann-Whitney U test; p = 5.2 3 10 À11 and 1.4 3 10 À4 ; CLES = 0.325 and 0.330) screens (Figures S4H and S4I) Meyers et al., 2017) .
Encouraged by these results, we adapted the approach to identify depleted circRNAs. A total of 171 circRNAs (11.3% of screened) were essential in at least one cell line ( Figure 4E ). In 91.8% of cases where a circRNA was essential, its linear counterpart was not ( Figure 4F ), suggesting that circRNAs drive cellular proliferation independent of their linear counterparts.
circRNA Essentiality Can Be Distinct from Parental Linear Transcripts
We randomly selected ten circRNAs that are essential in at least two cell lines for validation. Divergent primers across the backsplicing sites were designed to detect circRNAs. Sanger sequencing confirmed the junction sites, and RNase R treatment followed by qRT-PCR analysis confirmed their circularization ( Figures S4J and S4K ). All ten circRNAs predominantly localized in the cytoplasm ( Figure S4L ), agreeing with previous reports that most circRNAs localize outside of the nucleus (Jeck et al., 2013; Salzman et al., 2012) .
We then performed cell proliferation assays upon knockdown (KD) of each of these circRNAs with two individual shRNAs. qRT-PCR analyses confirmed KD efficiency of each shRNAs, with most of them resulting in >80% reduction of circRNA abundance ( Figure S4M ). A significantly decreased proliferation rate was observed in 38 out of 40 KD samples comparing to KD controls, validating their essentiality ( Figure 4G ). Although 6 out of 20 shRNAs had modest effects on linear RNA abundances, protein abundances were unaffected ( Figures S4M and S4N ). By contrast, for eight of the genes with validated antibodies, Figure S5 and Table S5. shRNAs targeting the linear form decreased the protein abundance in seven cases ( Figure S4N ). We thus reasoned that the effect on cellular proliferation observed in KD of circRNAs was not caused by off-target effect of the linear form. As a further confirmation, we investigated overexpression (OE) of these circRNAs and observed increased cell proliferation rate for 28 out of 40 OE samples, validating KD results ( Figures  4G and S4O ).
Among the ten parental linear transcripts, PHIP was the only one essential in our shRNA screens. Consistently, PHIP had the highest dropout level in Achilles CRISPR screens (Figures 4H and S4P) . Since the two shRNAs in our screen targeting PHIP did not affect its protein abundance ( Figure S4N ), we designed small interfering RNAs (siRNAs) to determine its effect on cell proliferation. As control, we also designed siRNAs for the seven non-essential genes with validated antibodies. We confirmed KD efficiency at both RNA and protein levels for six genes ( Figures S4Q and S4R ). A decreased proliferation rate was observed for PHIP and EZH2 in four and two cell lines, respectively ( Figure S4S ). Consistent with our shRNA and public CRISPR screens, no obvious change in the proliferation rate was observed for the other four genes ( Figure S4S ). These data emphasize the precision of our screen and show that most of the linear counterparts of the essential circRNAs are not themselves essential.
To determine whether there is redundancy in the function of circRNA isoforms, we performed KD rescue experiments by OE alternative isoforms with shared exons for nine of ten circRNAs ( Figure S5A ). Partial rescue was observed for five circRNAs, suggesting some functional redundancy ( Figure S5B ). Because our screen focused on highly abundant isoforms (Figure S5C) , functionality is likely dominated by the screened isoforms. Nevertheless, these studies highlight the possibility of functional interactions among circRNAs isoforms.
Functional Characterization of Essential circRNAs
We next sought to characterize functionality of the essential circRNAs. Of the ten circRNAs, circCSNK1G3 was of particular interest: its linear form was not essential in the four prostate cancer cell lines or any of the Achilles screens Meyers et al., 2017) . In contrast, circCSNK1G3 was essential in all four prostate cancer cell lines and two cell lines representing other tumor types ( Figures 4G and S5D-S5F ). circCSNK1G3 consists of three exons, with a total length of 536 base pairs (bp) and was present at similar abundance to its linear counterpart (circular:linear ratio: 0.79; Figures 5A and 5B ).
To investigate the mechanism by which circCSNK1G3 promotes cell proliferation, we performed RNA-seq in PC-3 cells after KD or OE of circCSNK1G3. Gene set enrichment analysis (GSEA) (Subramanian et al., 2005) showed that many genes upregulated in OE samples were downregulated in KD samples and vice versa ( Figures 5C and S5G ). A similar pattern was also observed for two other circRNAs, circSTAU2 and circGOLPH3 ( Figures S5H and S5I ), suggesting that phenotypes observed in KD and OE experiments were not caused by off-target effects. We identified 279 activated and 196 suppressed genes by circCSNK1G3 from the OE and KD studies ( Figure 5C ; Table  S5 ). We also performed RNA-seq analysis after CSNK1G3 KD and observed only six target genes shared by the circular and linear isoforms ( Figure 5D ). The most highly enriched terms for circCSNK1G3-activated genes were cell-cycle related (Figure 5E ), concordant with its promotion of cell proliferation. In contrast, the most highly enriched term for CSNK1G3-activated genes was ''response to acid chemical'' ( Figure 5F ), concordant with its reported function. These data suggest that circCSNK1G3 drives prostate cancer cell proliferation independent of its linear counterpart.
As circRNAs often function by interacting with microRNAs (miRNAs), we searched for candidate miRNAs interacting with circCSNK1G3. Through computational prediction and filtering with argonuate-crosslinking and immunoprecipitation sequencing (AGO-CLIP-seq) data (STAR Methods), we identified ten candidates. Using miRNA profiling data from a subset (n = 119) of the CPC-GENE cohort, we analyzed the correlation between miRNAs and circCSNK1G3. Five miRNAs, miR-181a/ b/c/d and miR-196b, were significantly correlated with circCSNK1G3 expression ( Figure 6A ; Table S6 ). Their predicted binding sites were located within highly conserved AGO-binding sites on exon 2 ( Figure 6B ). We then performed a RNA pulldown assay using biotinylated circCSNK1G3 and observed significant enrichment for only miR-181b/d ( Figure 6C ). By contrast, miR-7 was significantly enriched in ciRS-7 pulldown, while miR-181 and miR-196 were not ( Figure S6A ). The interaction was further confirmed by biotinylated miR-181b/d pulldown of circCSNK1G3 ( Figure 6D ). KD circCSNK1G3 decreased miR-181b/d abundance, while OE increased their abundance (Figure S6B) . A similar observation was reported for ciRS-7, where knockout of ciRS-7 downregulated its interactor miR-7 (Piwecka et al., 2017) . miR-181b/d OE in PC-3 cells significantly decreased CBX7 abundance, a well-characterized miR-181b target and a tumor suppressor in prostate cancer ( Figure 6E ) (Mansueto et al., 2010; O'Loghlen et al., 2012) . Consistent with downregulation of miR-181b/d upon circCSNK1G3 knockdown, CBX7 abundance was significantly increased ( Figure 6F ). Similarly, while cell-cycle genes such as CDK1 and CDC25A were upregulated in miR-181b/d OE cells, they were downregulated in circCSNK1G3 KD cells ( Figures 6E and 6F ). In agreement with upregulation of the cell-cycle genes, OE of miR-181b/ d increased PC-3 cell proliferation ( Figure 6G ). Importantly, OE of miR-181b/d significantly attenuated the cell-proliferation blockage induced by KD of circCSNK1G3 ( Figure 6G ). Taken together, these data suggest that circCSNK1G3 promotes cell proliferation at least partially through interaction with miR-181b/d.
DISCUSSION
Most current transcriptome sequencing of human tumors is done with poly-A capture and modest sequencing depth, limiting our understanding of low-abundance and non-poly-A transcripts and making an integral part of gene transcriptional regulation elusive. The resource generated here allowed us to systematically characterize such transcripts, linking these to aggressive clinical and pathologic features of prostate cancer.
Many studies have reported circRNAs modulating linear products of their parental genes (Abdelmohsen et al., 2017; Hansen et al., 2013) . However, in $90% of circRNAs identified as essential for proliferation, their linear counterparts were not, suggesting an independent function for circular transcripts. Despite being extensively investigated, modulation of linear abundance might only account for a subset of circRNA function. In agreement with this, circRNAs showed distinctive prognostic information from their linear counterparts, hinting at distinctive clinical roles.
For most circRNAs, restricting shRNA design to encompass the back-splicing site is necessary to ensure unambiguous KD of the circular transcripts. Nevertheless, such restriction inevitably results in overlapping shRNAs that might bias the screen results. Approaches such as RNA-based CRISPR assays may be useful for future cross-validation studies as techniques mature.
circRNAs are known to act as miRNA sponges (Chen, 2016) . Recently, an alternative stabilization mechanism has been suggested for ciRS-7 (Piwecka et al., 2017) . We show evidence supporting the miRNA stabilization mechanism. However, functional interactions, pervasiveness of stabilization, and the underlying mechanisms remain to be elucidated. It is also worth noting that the regulation of miR-181b/d partially conveys function of circCSNK1G3; similarly, miR-181b/d interaction beyond circCSNK1G3 could exist concurrently.
In summary, we reported for the first time a circRNA transcriptional landscape with functional annotation in localized prostate cancer and presented a rich resource for future transcriptome research. These data highlight the value of deep RNA-seq analysis of primary tumors, particularly using protocols that detect non-poly-A transcripts.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
The HEK293FT cell line was obtained from ThermoFisher (Cat. #R70007). Cancer cell lines (LNCaP (Cat. #CRL-1740), 22Rv1 (Cat. #CRL-2505), PC-3 (Cat. #CRL-1435), HCT-116 (Cat. #CCL-247), and A549 (Cat. #CCL-185) were obtained from the American Type Culture Collection (ATCC). The V16A cells were established by the Zoubeidi lab (Bishop et al., 2017) . HEK293FT was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% Non-Essential Amino Acids (NEAA) (ThermoFisher Cat. #11140-050) and 1% L-Glutamine (ThermoFisher, Cat. #25030-081), 10% FBS (Wisent, Cat. #080150) and 1% penicillin streptomycin (Wisent, Cat. #450-201-EL) solution in the presence of 500 mg/mL G-418 (Geneticin) (Sigma-Aldrich; Cat. #4727894001), while HCT-116 was cultured in McCoy's 5a Medium Modified media, A549 and the four prostate cancer cell lines were maintained in RPMI 1640 medium, all supplemented with 10% FBS and 1% penicillin-streptomycin. All cells were cultured at 37 C in 5% CO2. All cell lines were authenticated by STR every 6 months and tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza, Cat. #LT07-118). All cell lines are of male Homo sapiens origin.
Patient sample collection
The study comprised 193 men with prostate cancer. Tumor samples from the CPC-GENE (n = 144) and NGS-ProToCol (n = 49) cohorts were collected independently as described below. For the CPC-GENE cohort (Canadian Prostate Cancer Genome Network), patient selection, sample collection and processing procedures were performed as previously described . Informed consent, following guidelines from local Research Ethics Board (REB) and the International Cancer Genome Consortium (ICGC), was obtained at time of clinical follow-up. Previously collected tumor tissues were used according to University Health Network and CHU de Qué bec-Université Laval REB-approved study protocols (UHN 06-0822-CE, UHN 11-0024-CE, CHUdeQ-UL 2012-913:H12-03-192). Biochemical recurrence (BCR) in this study was defined as two consecutive measurements of PSA greater than 0.2 ng/mL with BCR time backdated to time of first measured PSA rise. Based on pre-surgical parameters, patients are all intermediate-risk according to National Comprehensive Cancer Network (NCCN) definitions. Gleason scores and tumor cellularity were evaluated by two genitourinary pathologists (T.v.d.K and B.T.) on scanned hematoxylin-and eosin-stained slides . Cellularity was also determined in silico from Oncoscan SNP arrays via qpure (v1.1) (Song et al., 2012) .
For the CTMM NGS-ProToCol study (NGS-ProToCol, Next Generation Sequencing from Prostate to Colorectal Cancer -Center for Translational Molecular Medicine (2014-2015); https://www.lygature.org/ctmm-portfolio), 49 prostate cancers from the Erasmus MC were snap-frozen and stored in liquid nitrogen as previously described by Hendriksen et al. (Hendriksen et al., 2006) . Use of the samples for research purposes was approved by the Erasmus MC Medical Ethics Committee according to the Medical Research Involving Human Subjects Act (MEC-2004-261; MEC-2010-176) .
METHOD DETAILS
One sample per patient was collected for RNA sequencing. For shRNA-based loss-of-functional screen and cell line RNA-Seq, duplicate samples were collected. All the cell line-based molecular experiments were performed in triplicates unless otherwise specified. No randomization or blinding is required, and all data listed were included for analysis unless otherwise specified in the relevant figure legend and detailed method section. For correlative studies in patient cohorts, samples were dichotomized according to abundance of the tested molecules or as indicated in the relevant figure legend of methods section.
Tumor and cell line RNA-Sequencing
For the CPC-GENE cohort, total RNA was extracted with mirVana miRNA Isolation Kit (Life Technologies) according to manufacturer's instructions. RNA samples were sent to BGI Americas where it underwent QC and DNase treatment. For each sample, 200 ng of total RNA was used to construct a TruSeq strand-specific library with the Ribo Zero protocol (Illumina, Cat. #RS-122-2203) . The libraries were sequenced on a HiSeq 2000 to a minimal target of 180 million, 2 3 100 bp paired-end reads.
For the NGS-ProToCol cohort, RNA was extracted using RNA-Bee (Campro Scientific, Berlin, Germany) and the library prepared for RNA-Seq used the NEBNext Ultra Directional RNA Library Prep Kit for Illumina with rRNA reduction. The sample preparation was performed according to the protocol 'NEBNext Ultra Directional RNA Library Prep Kit for Illumina' (NEB, Cat. #E7420S/L and E6310S/L/X). Briefly, rRNA was reduced using RNase H-based method. Then, fragmentation of the rRNA reduced RNA and a cDNA synthesis was performed. This was used for ligation with the sequencing adapters and PCR amplification of the resulting product. The quality and yield after sample preparation were measured with the Fragment Analyzer (Advanced Analytical). Clustering and DNA sequencing using the Illumina cBot and HiSeq 2500 was performed according to manufacturer's protocols. A concentration of 16.0 pM of DNA was used as input. HiSeq control software HCS (v2.2.58) was used. Image analysis, base calling, and quality check was performed with the Illumina data analysis pipeline RTA (v1.18.64) and Bcl2fastq (v2.17). The 126 bp stranded Illumina HiSeq 2500 paired-end reads have a peak in fragment size of 300-600 bp and the samples have an average depth of 70 million paired-end reads.
For cell line RNA-Seq, total RNAs purified with RNeasy Mini Kit (QIAGEN, Cat. #74106), and the DNA was digested by RNase-Free DNase Set (QIAGEN, Cat. #79254) during the RNA purification. For the preparation of the RNA-Seq libraries for the four cell lines, 10 mg of total RNA was subjected to RiboMinus for the removal of the ribosomal RNA by using the RiboMinus Human/Mouse Transcriptome Isolation Kit (ThermoFisher, Cat. #K155001). After RiboMinus treatment, the samples ($1 mg left) were divided into two equal portions, one treated with RNase R and the other incubated only with the digestion buffer. Samples were cleaned-up by phenol-chloroform before resuspension in a small volume of RNase-free H 2 O. The library preparation commenced directly with the fragmentation step by mixing the sample and the Fragment, Prime, Finish Mix in the TruSeq Stranded mRNA Library Prep Kit (Illumina, Cat. #RS-122-2101) at a 1:1 ratio, followed by the manufacturer's protocol for the remainder of the procedure. RNA-Seq libraries were sequenced as paired-end reads in duplicates at $50 million reads per library using HiSeq 2000 platforms.
RNA-Seq libraries for circCSNK1G3, circGOLPH3, circSTAU2 and CSNK1G3 were constructed with the kit from Illumina (TruSeq Stranded mRNA Library Prep Kit) according to the manufacturer's protocol as described above. RNA-Seq libraries for circCSNK1G3 and shRNA screen were sequenced as 76 bp and 58 bp single-end reads in duplicates at $30 and $70 million reads per library using HiSeq 2000 platforms respectively. RNA-Seq libraries for circGOLPH3, circSTAU2 and CSNK1G3 were sequenced as 2 3 150 bp paired-end reads in duplicates at $40 million reads per library using NovaSeq platforms.
Loss of Function shRNA Screen on circRNAs in Cell lines
To perform functional genomic screen for individual circRNA, the top 2,000 most abundant circRNAs in prostate cancer cell lines were selected. For each circRNA, a 34-nucleotide long sequence around the junction site, with 17 nucleotides on each side, was extracted. A custom script was developed to perform batch shRNA designing with the GPP web portal (https://portals. broadinstitute.org/gpp/public/seq/search). To minimize off-target effects, all candidates were aligned back to human Refseq transcripts by BLAST, and a specificity factor was calculated to calibrate the intrinsic score. Finally, all potential targets were sorted by the adjusted score. For circRNA parental transcripts, the shRNA candidates were scanned from the TRC shRNA library. Those targeting the region where corresponding circRNA are derive from were removed.
shRNAs were synthesized as 92-mer oligonucleotides (CustomArray), GGAAAGGACGAAACACCGGNNNNNNNNNNNNN NNNNNNNNCTCGAGNNNNNNNNNNNNNNNNNNNNNTTTTTGAATTCTCGACCTCGAGACA (N's denote shRNA 21nt-target sequence, sense and anti-sense) with a density of $12,000 sequences, and amplified by PCR as a pool using the following primers: TAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGG (Forward) and CCCCCTTTTCTTTTAAA ATTGTGGATGAATACTGCCATTTGTCTCGAGGTCGAGAATTC (Reverse). The PCR product was purified and then cloned in the pLKO.1 vector using AgeI/EcoRI (NEB, Cat. #R3101S and Cat. #R3553S) sites. Ligation was performed using the NEBuilderâ HiFi DNA Assembly Cloning Kit (NEB, Cat. #E5520S) and transformed into an electrocompetent strain (Stbl4, ThermoFisher, Cat. #11635018) to achieve > 300X coverage. Colonies were scraped off plates using LB and plasmid DNA was extracted (NA0310 Sigma GenElute HP Plasmid Maxiprep Kit). The library was submitted for next generation sequencing to confirm adequate library representation of each shRNA.
Library virus was generated in HEK293FT cells and each cell line was titrated with library virus to achieve a low MOI. The MOI was determined as previously described (Shalem et al., 2014) . Specifically, MOI was determined by infecting five million cells with varying amounts of library virus for 24 hours, which were then passaged into media with or without puromycin (ThermoFisher; Cat. #A11138-03) for 48-72 hours (PC-3, 3.5 mg/mL; 22Rv1, V16A, 3 mg/mL; LNCaP, 2.5 mg/mL). A ratio between these two populations was calculated to determine the infection efficiency to achieve a MOI of $0.3. The amount of library virus was scaled up along with the number of cells to ensure that on average every shRNA was represented in 300 cells. In the screens, cells were split into triplicates, passaged every 3-4 days, and maintained at 300x coverage for the duration of the screen. Cells were sampled in replicates on Day 0 (T0), Day 8 (T8) and Day 16 (T16) post-selection for genomic DNA analysis. In brief, genomic DNA was extracted for replicate samples (QIAamp Blood Midi kit, Cat. #51183) and shRNA inserts were amplified by PCR using standard Illumina next-generation sequencing library preparation kit. The input amount of genomic DNA was calculated to achieve $250x coverage of the library, which was then sequenced on an Illumina HiSeq 2500.
Essential circRNAs were identified from shRNA screen sequencing results with MAGeCK (v0.5.4) software (Li et al., 2014b) . Sequencing FASTQ files were first trimmed so that shRNA sequence starts at the first base. The counts of each shRNA in different time points were then counted from the trimmed files with MAGeCK 'count' function with default parameters. The Robust Rank Aggregation (RRA) algorithm was applied on the count table. A P value of 0.01 was used as threshold for essentiality.
Plasmid Construction
The circRNA and linear KD lentiviral expression vectors were constructed by inserting a phosphorylated short double-strand hairpin oligo (Table S6 ) into the pLKO.1 vector (Moffat et al., 2006) . The same vector carrying the shRNA targeting GFP was used as a KD control. Plasmids for circRNA OE were constructed using pcDNA3.1(+) circRNA Mini Vector, which was a gift from Jeremy Wilusz (Addgene plasmid # 60648). The region spanning all the exons that constitute the circRNAs were PCR amplified from cDNA and seamlessly cloned (NEB, Cat. #E5520S) between the splicing signals AG and GT which is surrounded by the minimal introns that facilitate the generation of circZKSCAN1 (Liang and Wilusz, 2014) .
Real-time PCR
Total RNA from the cell lines was purified with RNeasy Mini Kit (QIAGEN, Cat. #74106), and the DNA was digested using RNase-Free DNase Set (QIAGEN, Cat. #79254) during the RNA purification. RNA from nuclear and cytoplasmic fractions was isolated using PARIS kit (Ambion, Cat. #AM1921) following the manufacturer's specifications. U6 and GAPDH were introduced here to act as the quality control of the fractionation.
For the RNase R treatment, one mg total RNA was incubated for 15 min at 37 C with or without 10 U RNase R (Epicenter, Cat. #RNR07250,) followed by phenol-chloroform (ThermoFisher, Cat. #15593-049) purification. cDNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Cat. #4368814).
Divergent primers to detect circRNAs were designed for PCR products of sizes ranging from 100-150 bp and spanning the junction site. Convergent primers that targeted the parental linear mRNA counterparts were exclusive of the circRNA generating region for the same size range. Expression levels of circRNAs and their parental linear RNAs were quantified using the primers listed in (Table S6) and PowerUp SYBR Green Master Mix (Applied Biosystems, Cat. #A25742,) in StepOnePlus Real-Time PCR System (Applied Biosystems) or CFX96 Touch Real-Time PCR Detection System (Bio-Rad). RPS28 was used as the endogenous control gene. The results of qRT-PCR were analyzed by the 2 -DD CT method. miRNA Detection Total RNA was extracted from shRNA knockdown and overexpression circCSNK1G3 samples in PC-3 cells with miRNeasy Mini Kit (QIAGEN; Cat. #1038703), and reverse transcribed by miScript II RT kit (50) (QIAGEN; Cat. #218161). qPCR was performed with miScript SYBR Green PCR Kit (QIAGEN; Cat. #218075). Relative expression levels of miRNAs were detected with miScript primer assays from QIAGEN (Cat. #MS00006685 for 181a, Cat. #MS00006699 for 181b, Cat. #MS00003612 for 181c, Cat. #MS00003619 for 181d, Cat. #MS00006734 for 196b, Cat. #MS 00032116 for miR-7). SnRNA U6 (RNU6-2) (QIAGEN; Cat. #MS00033740) was used as an internal control.
Transfection and overexpression
Control siRNA and all siRNAs targeting linear and circular candidate genes were purchased from ThermoFisher. siRNA catalog numbers or sequences are listed in Table S6 . Lipofectamine RNAiMax reagent (ThermoFisher; Cat. #13778150) was used to transfect siRNAs. 3 3 10 5 cells were plated in 6-well plates overnight and transfected the next day with the transfection mixture (9 mL lipofectamine RNAiMax and 30 pmol siRNAs in Opti-MEM I Reduced Serum Medium (ThermoFisher; Cat. #31985070)) for at least 24 hours before cell collection and downstream experiments.
Prostate cancer cells were transfected with 1.2 mg circRNA overexpressing plasmids or empty vector by lipo3000 transfection reagent (ThermoFisher, Cat. #L3000015) as per the manufacturer's protocol. The transfected cells were harvested 24 hours after transfection for RNA extraction or other assays.
Cell Proliferation Assays
Two thousand cells per well were seeded in a 96-well cell culture plate (Falcon, Cat. #353072). Cells were imaged for 7 days using IncuCyte ZOOM live cell imaging system (Essen BioScience, MI USA) and the surface area occupied by the cells was calculated, which was then expressed as percent cell confluence. shRNAs targeting GFP were used as control for shRNA KD assays, and empty OE vector was used as control for OE assays.
Lentivirus Production and Infection for Individual Validation
The shRNA expressing lentiviral transfer vector was transfected together with the packaging (psPAX2) and envelope plasmid (pMD2.G) by lipo3000. The medium was harvested at 24 and 48 hours after transfection before storing at À80 C. For infection, 5 3 10 4 cells were seeded per well in six-well plates and infected with lentivirus on the next day. Infected cells were selected with 3 mg/mL puromycin (2.5 mg/mL for LNCaP).
RNA Pull-Down
The miRNA pull-down was carried out using in vitro transcribed biotinylated RNA probes. The DNA templates were prepared by PCR using the T7 promoter containing primers (see Table S6 ). The RNA probes were prepared by using the TranscriptAid T7 high yield transcription kit (ThermoFisher; Cat. #K0441) following the manufacturer's protocol. Biotinylated UTP was incorporated into the probes by adding the Bio-16-UTP (ThermoFisher; Cat. #AM8452) into the reaction system at a ratio of 1:4 (Bio-16-UTP: unlabeled UTP). Template DNA was removed by 1 U RNase-free DNase (Promega, Cat. #M6101) at 37 C for 30 min. The RNA product was then purified by canonical phenol-chloroform extraction. 60mL (for each sample) of streptavidin beads (ThermoFisher; Cat. #65002) underwent a preclear washed by incubating with 500 mL of lysis buffer supplemented with 0.2 mg/mL yeast tRNA (ThermoFisher; Cat. #AM7119) for 2 hours at 4 C. 1x10 7 cells were washed with cold PBS. 1 mL lysis buffer (25 mM Tris-HCl pH 7.4 (made by Trizma base, Sigma-Aldrich, Cat. #T1503), 150 mM NaCl, 1 mM EDTA (ThermoFisher; Cat. #15575020), 1% IGEPAL CA-630 (Sigma-Aldrich; Cat. #I8896) and 5% glycerol) was added to the cells in the presence of protease inhibitor cocktail (Roche, Cat. #11836170001) and RNase inhibitor (ThermoFisher; Cat. #EO0381), and the reaction was kept on ice for 15 min. The lysate was collected and transferred to a microcentrifuge tube, then centrifuged at $14,000 g for 15 min to pellet the cell debris before transferring the supernatant to a new tube. in vitro transcribed biotinylated RNA (3 mg) was added into the cell lysate supernatant and incubated at room temperature for one hour with rotation. Pre-cleaned magnetic beads were then added and incubated for an additional hour with rotation. The RNA-bead complexes were collected using DynaMag-15 magnetic strip before washing six times with lysis buffer. RNA was eluted and extracted by TRIzol (ThermoFisher, Cat. #15596026).
For pull-down circCSNK1G3 by miRNA mimics, 3 0 end biotinylated miRCURY LNA Premium miRNA Mimic (Cat. #YM00479902-BDI, Cat. #YM00473515-BDI, Cat. #YM00472825-BDI) was transfected into 5x10 6 PC-3 cells at a final concentration of 20 nM by RNAiMAX (ThermoFisher; Cat. #13778150) following the manufactures protocol. After 24 hours, cells were lysed in lysis buffer described above and the same pull-down procedure was performed. Western blotting Cells (2 3 10 5 ) were washed by cold PBS and then lysed with 150 mL of RIPA buffer (ThermoFisher; Cat. #89901) in the presence of protease inhibitor cocktail (Roche; Cat. #11836170001) on ice for 15 min. The lysate was then centrifuged at 15, 000 g at 4 C for 10 min to remove cellular debris. The supernatant was transferred to a new tube and boiled at 70 C for 10 min after the addition of Blot LDS Sample Buffer (ThermoFisher; Cat. #B0007) and Bolt Sample Reducing Agent (ThermoFisher; Cat. #B0004). Protein samples were separated by Bolt 4%-12% Bis-Tris Plus Gels (ThermoFisher; Cat. #NW04127BOX) and transferred onto PVDF membranes (Bio-Rad; Cat. #17001917). Membranes were blocked and incubated with the appropriate primary and secondary antibodies. Primary antibodies used were Cat. #ab37950 (CSNK1G3), Cat. #ab69171 (GOLPH3), Cat. #ab197083 (UBAP2), Cat. #ab191250 (EZH2) and Cat. #ab62194 (PSD3) from Abcam; Cat. #ABS615 (PHIP) from Millipore; Cat. #PA5-38772 (RPS6KC1) from Thermo-Fisher; Cat. #sc-47724 (GAPDH), Cat. #sc-81896 (ASAP1) from Santa Cruz; Cat. #13901s (Vinculin) from CST. Secondary antibodies used were anti-mouse (CST; Cat. #7076S) and anti-rabbit (CST; Cat. #7074S). Antibody-bound proteins were visualized by ECL substrate (ThermoFisher; Cat. #34096).
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using R statistical environment (v3.4.1) (R Development Core Team, 2017) . For cell line experiments, data were shown as mean ± SD, ''n'' represents the number of technical replicates. Biological replicates were shown separately unless otherwise stated in figure legend. The type of test method used for statistical analysis was specified in the text where the results were described and details for the test can be found in the relevant figure legend and method section. All tests were two-sided unless otherwise specified. For survival analysis, the assumptions of the Cox proportional hazards model were tested using the 'cox.zph' function in the R Survival package (v2.41-3) (Therneau and Grambsch, 2013) with 0.1 as cut-off. A log-rank test was used when the cox.zph test failed (see 'Univariate Survival Analysis' section). Asterisks define significance levels (* p < 0.05; ** p < 0.01; *** p < 0.001).
RNA-Sequencing Data Processing
To measure RNA abundance, RNA-Seq reads were mapped to GRCh37 with Gencode (Harrow et al., 2006) v24lift37 annotation using STAR (v2.5.3) (Dobin et al., 2013) . The GeneCounts parameter was set to TranscriptomeSAM and the resulting bam file was used as input to the rsem-calculate-expression program (v1.3.0) (Li and Dewey, 2011) . To ensure robustness of our results, we also quantified RNA abundance using raw counts from STAR by setting the GeneCounts parameter to quantMode. Trimmed Means of M-Values (TMM) normalization was performed on the library size adjusted read counts before being converted to FPKM with the Bioconductor package edgeR (v3.12.1) (Robinson et al., 2010) . Total exon length was calculated using the GenomicFeatures package (v1.28.5) (Lawrence et al., 2013b) and used in the FPKM calculation. Read level quality control metrics were obtained using FastQC (v0.11.5) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and BAM alignment quality metrics were obtained using RSeQC .
TCGA RNA-Seq bam files were downloaded from the GDC and back-extracted to FASTQ files. FASTQ files were aligned using STAR (v2.5.3) and abundance was calculated using RSEM (v1.3.0) as above. Similarity of each CPC-GENE sample to TCGA subtypes was calculated using the top 25% of RNAs detected in all CPC-GENE samples, as ordered by interquartile range. The median abundance for each gene was calculated in the eight previously identified TCGA subtypes (Cancer Genome Atlas Research Network, 2015) to create a median abundance profile for each. CPC-GENE samples were then assigned to the TCGA subtype to which it had the highest Spearman's correlation.
RNA-Sequencing Subtype Development
Consensus clustering (ConsensusClusterPlus v1.38.0) (Wilkerson and Hayes, 2010) was performed on the top 25 percent (n = 4,582) of most variable RNA transcripts in all samples (n = 144) ordered by interquartile range. Z-scores of RNA abundance were used for clustering. We evaluated a maximum of 18 clusters, and used 80% gene resampling and 80% item resampling with 1000 iterations. Hierarchical clustering was performed using Euclidean distance and Ward linkage. Clustering of samples and transcripts were performed separately. The optimal cluster number (k = 5) was chosen based on the delta area, which is the relative change in the area under the CDF curve comparing k and k-1. Silhouette scores were calculated with the cluster (v2.0.7-1) package (https://cran. r-project.org/web/packages/cluster/citation.html).
Subtype Associations with Clinical and Genomic Features
RNA subtypes were associated with genomic and clinical features. Continuous clinical features including pre-treatment PSA and age at diagnosis were tested for association using an ANOVA, while binary features such as Gleason Score and T category were tested using Pearson's c 2 test (R Development Core Team, 2017) . Binary genomic features including copy number aberrations (CNAs) were also tested for association using two-sided proportions test. Summary features such as percent genome altered (PGA) were tested for association using an ANOVA.
Estimation of Infiltrating Immune Cells
To determine the cytolytic activity of samples, the mean abundance of GZMA and PRF1 was calculated using FPKM values . To determine the level of infiltrating immune cells, we used data from matching mRNA arrays (n = 136) available in the Gene Expression Omnibus under the accession GSE84043. The 'Estimate of STromal and Immune cells in Malignant Tumors' (ESTIMATE) method was used, as implemented in the estimate R package (v1.0.11) (Yoshihara et al., 2013) .
Fusion Gene Analysis
Fusions genes for our intermediate-risk prostate cancer and the SU2C mCRPC dataset were identified using FusionCatcher (v0.99.4e) with default parameters and processed by collapsing multiple events involving the same gene pair into a single call (Nicorici et al., 2014) . The mapper used in FusionCatcher was Bowtie (v1.0.0), Bowtie (v2.2.6) (Langmead and Salzberg, 2012) , Star (v2.4.2) (Dobin et al., 2013) and BLAT (v0.35) (Kent, 2002) . Fusions were considered recurrent if they occurred in greater than 10% of the cohort.
Fisher's Exact test was used on all pairwise combinations of the recurrent fusion events to determine if they tended to co-occur together or were mutually exclusive. P values were corrected for multiple-testing using FDR. Permutation tests with one million replicates were used to determine if the number of co-occurring fusions was greater than expected by chance alone.
Associations between recurrent fusions and clinical Gleason score, T category, BCR, pre-treatment PSA and age at treatment were calculated using a Spearman's r for continuous features, a Cox proportional hazards for BCR and a Mann-Whitney U test for binarized features. For clinical Gleason score, patients were divided based on whether they have primary Gleason 3 or primary Gleason 4. For clinical T-category, patients were divided based on whether their tumors were T1 or T2. P values were corrected for multiple testing using FDR.
A previously reported set of 40 drivers in localized prostate cancer was used to identify 16 drivers occurring in at least five samples from this cohort, then tested for associations with specific fusions and with fusion burden . SLC45A3:ELK4 was removed from the fusion set because only four patients lacked the fusion. Fusion counts and read-through fusion counts refer to the total number of all detected fusions and read-through fusions in each sample. Association tests were performed for all pairwise combination of the twenty fusions and two fusions counts against the 25 filtered features. Proportion test were used to evaluate associations between fusions and binary features such as presence or absence of mutations. A Mann-Whitney U-test was used to test for associations between fusions and continuous feature like mutation burden and methylation and fusion counts against binary features. Spearman's r was used to test for associations between fusion counts and continuous features. P values were adjusted for multiple-testing using FDR.
To test if fusions were enriched in the SU2C dataset relative to our cohort, we first took the subset of the recurrent fusions found at a higher frequency in the SU2C cohort. Subsequently, we fit a logistic model with an odds offset accounting for the higher overall fusion burden in the metastatic samples. For fusions that were absent in one group, a Fisher's Exact test was used. P values were adjusted using FDR separately.
circRNA Identification RNA-Seq reads were mapped to GRCh37 using Tophat (v2.1.0) (Trapnell et al., 2009) with Gencode (v24lift37) annotations. The maximum splice region mismatches number allowed was set to 2 (-m 2) and alignment to micro-exons was turned on (-microexon-search). Unaligned reads were converted to fastq format with bamToFastq function from the Bedtools suite and used to call fusion with TopHat-Fusion (v2.1.0), with anchor length set as 20 bp (-fusion-anchor-length 20) and coverage-based junction search disabled (-no-coverge-search). The resulting fusion reads were annotated with CIRCexplorer (v1.1.10) . Genes where the circRNA is derived is referred to as a parental gene.
circRNAs identified from each sample were merged together and numbers of back-splicing reads were extracted to measure abundance. An effective length for circRNA was determined to be twice the read length less twice the anchor-size. As only reads on this range could be unbiased evidence supporting circRNA. FPKM was calculated using edgeR (v3.12.1) (Robinson et al., 2010) with this effective circRNA length and normalized using library sizes and normalization factors extracted from linear transcripts in the same RNA-Seq sample. Multiple circRNAs generated from the same gene were treated separately unless specified. Gene level quantification for circular transcripts were calculated as the mean of multiple circRNAs from the same gene using R package plyr (v1.8.4) (Wickham, 2011) .
Only circRNAs with more than one junction reads (reads encompassing back-splicing site) across 144 patient samples or 16 cell line samples were kept. The overlap of patient sample and cell line identified circRNAs were further filtered so that each of them has more than 1.5-fold enrichment after RNase R treatment. These overlapping enriched circRNAs are our high-confidence discovery set.
circRNA Abundance Analysis The negative binomial (NB) distribution was previously proposed to model RNA-Seq read counts for linear transcripts (Robinson et al., 2010) . By analogy, we tested the read counts of BSRs for circRNA against the NB model. Raw reads from each of the 144 patient samples were used to fit a negative binomial distribution using the R package 'fitdistrplus' (v1.0-9) (Delignette-Muller and Dutang, 2015) . Expected counts were generated from a standard negative binomial model with parameter extracted from the fitted model. Raw counts were then compared with their corresponding expected counts from the NB model. The Kolmogorov-Smirnov test was used to calculate a P value. A linear model was fitted with quantiles of raw counts as response and expected counts as predictor. R 2 values were extracted from each of fitted models and used as a measure for the fitness of a NB distribution to model circRNA read counts ( Figures S2A and S2B ).
circRNA Characterization A total of 141,124 circRNAs were downloaded from circBase (Gla zar et al., 2014) (http://circbase.org, Dec. 15th, 2015 version) and annotated according to their tissue of origin and disease status. The data was pooled together with circRNAs identified from our prostate cancer patient and cell line samples and resulted in a total of 184,424 unique circRNAs.
A matrix with rows representing unique circRNAs and columns representing the source of study was produced. Binary values were used to denote the presence or absent for circRNA in each source. For visualization, circRNAs show the same patterns when collapsed into a new matrix so that each new row represents a group of 20 circRNAs with the same pattern. Columns were ordered using hierarchical clustering with default parameter, and rows were then ordered by descending value, with any ties being broken by values in the following column. circRNAs (4,284, 2.32% of total) that could not be collapsed were visualized separately in supplementary figure.
Consensus clustering was performed on the high-confidence circRNA set on samples from the CPC-GENE cohort (n = 144) with the R package ConsensusClusterPlus (v1.38.0) (Wilkerson and Hayes, 2010) . circRNA z-score was calculated across samples before cluster, hierarchical clustering was performed using Euclidean distance and Ward linkage. We evaluated a maximum of 18 clusters, used 80% gene resampling and 80% item resampling with 1,000 iterations.
Hexagon bin plots were produced using ggplot2 (v3.1.0) (Wickham, 2016) in R, all other visualization were achieved using BPG (v5.9.8) for R (P'ng et al., 2017) .
circRNA Genomic Localization Analysis Public datasets were interrogated to determine replication timing of the DNA regions around circRNAs. We retrieved replication timing values at 100 kbp resolution from previously published work (Lawrence et al., 2013a) . The 25,036-high confidence circRNAs were annotated with replication time, and unannotated entries removed. The remaining 24,384 circRNAs were used to calculate the mean replication time. To generate a null distribution, we randomly sampled 24,384 replication times with replacement at a chromosomal frequency matching the observed high confidence circRNAs, then calculated the mean, and repeated a million times. The empirical P value was the fraction of replicates with a value as or more extreme than observed experimentally, with the addition of one pseudo-count to provide a lower-bound.
Fusion circRNA Analysis
A refFlat format reference was created using fusion genes detected in the CPC-GENE cohort. Only fusions from the same strand were used. CIRCexplorer was then run again on the bam files output from tophat-fusion with the refFlat as reference to annotate backspliced reads. Only fusion circRNAs (f-circRNA) supported by reads encompassing the linear fusion genes break points and a minimum of two back-spliced reads were kept. The resultant f-circRNAs were filtered so that only those with a corresponding linear fusion gene detected in the same sample were retained.
Gene Enrichment Analysis
Gene enrichment analysis was performed with R package gProfileR (v0.6.4) (Reimand et al., 2016) . FDR method was used for multiple hypotheses testing correction (correction_method = 'fdr') and gene ontology annotation was used as source (src_filter = 'GO'). Different statistical background was provided: for RNA-Seq based differential expression analysis, all coding genes were used; to obtain features for building a machine learning predictor, all genes from the training set were used; and for parental gene enrichment, all genes in the annotation were used.
The R package clusterProfiler (v3.4.4) (Yu et al., 2012) was used to perform pre-ranked gene set enrichment analysis on the log 2 transformed fold change calculated from gene FPKM with one pseudo-count. For gene sets with more than 200 genes, the top 200 genes ranked by fold change in decreasing (for upregulated gene set) or increasing (for downregulated gene set) order were used.
Predictive Model Generation
To generate a predictive model that can distinguish parental genes from non-parental genes, genomic and functional signatures of 5,813 parental genes (positive set) and 5,503 non-parental genes (negative set) was used (Table S2 ). Eight genomic and functional features of parental and non-parental genes were used for classification (Table S2 ). CNA information was acquired from previous study and all other genomic features was calculated from the reference gtf file. For the functional feature (GO-enriched), gene enrichment analysis was performed on genes in the training set first (see 'Gene Enrichment Analysis' section). All genes from the significantly enriched terms were used to annotate. All datasets (positive set + negative set) were divided into two groups to build a predictive model: training set (50% of dataset) and test set (50% of dataset). A predictive model was created by integrating all tested genomic and functional signatures with random forest machine learning techniques (Fan et al., 2011; Yan et al., 2012) . Parameters for random forest (mtry and ntree) were optimized by grid-search using 5-fold cross validation with ten repeats of the randomization. To optimize parameters and build the predictive model, we used the R package randomForest (v4.6-12) (https://cran.r-project.org/doc/Rnews/Rnews_2002-3.pdf). We performed 10,000 iterations on data partitioning and predictive model building. Mean values from the 10,000 iterations were used to generate plots.
Calculation of CRI
CRI was calculated on the subset of circRNAs detected in more than half of the samples. CRI for a sample was defined as the number of circRNAs with higher than its mean abundance in the given sample:
Let rows of the matrix be the subset of circRNAs and columns be patient samples, x ij is the value of the i-th row and j-th column, the x i is the mean of i-th row, a ij = x ij À x i and have fða ij Þ = 1 a ij >0 0 a ij %0 for i = 1; 2; .; n i ; j = 1; 2; .; n j :
(1) n i is the number of rows of matrix,n j is the number of columns of matrix, and y j represents the sum of fða ij Þ in j -th column, y = ½y 1 ; y 2 ; /; y nj . y j = X n i i = 1 fða ij Þ (2) y j is CRI for sample j.
Univariate Survival Analysis
Univariate survival analysis was performed on circRNAs and their linear counterparts. Assumption for the Cox proportional hazards models was tested using the cox.zph function in the R Survival package (v2.41-3) (Therneau and Grambsch, 2013) with 0.1 as cutoff. Cox proportional hazards model was then fit using patient groups dichotomized by median abundance and BCR as endpoint. Data visualization was performed using the BPG (v5.9.8) library for R (P'ng et al., 2017) .
Circular-microRNA analysis
Predicted miRNAs with binding sites on circCSNK1G3 and peak files for AGO binding were downloaded from starBase (Li et al., 2014a) . AGO sites appear in at least 10% of the samples were kept. NanoString evaluation of 792 miRNAs was collected and Spearman correlation between circCSNK1G3 and miRNAs were calculated. Five miRNAs with significant expression correlation with circCSNK1G3 (p < 0.05, j r j>0.2) and predicted binding within AGO sites were selected for downstream investigation. To visualize miRNA binding on the circCSNK1G3 transcript, the ecolitk R package (v1.48.0) (https://www.bioconductor.org/packages/ release/bioc/html/ecolitk.html) was used, with phastCons score for 99 vertebrate genomes annotation from UCSC (http:// hgdownload.soe.ucsc.edu/goldenPath/hg19/multiz100way).
DATA AND SOFTWARE AVAILABILITY
CPC-GENE data have been deposited in the European Genome-phenome Archive (EGA) under the accession number EGA: EGAS00001000900 (https://www.ebi.ac.uk/ega/studies/EGAS00001000900). The NGS-ProToCol data can be found at EGA: EGAS00001002816 (https://www.ebi.ac.uk/ega/studies/EGAS00001002816). Cell line RNA-Seq and shRNA screen data are deposited in the Gene Expression Omnibus (GEO) under the accession number GEO: GSE113124 (https://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE113124). 
